Rover Labs Acquires Genophyll Labs LLC
Acquisition allows emerging startup to expand product and testing services in tri-state area.
"Our team is excited to become part of the Rover Labs family", said Aditi Luthra, Founder & CEO of Genophyll Labs. "We look forward to continuing our relationships with our valued customers while accumulating new clients."
Genophyll Labs provides fast, reliable, nasal swab COVID-19 PCR testing, while Rover labs specializes in saliva COVID-19 PCR testing. This synergy will increase productivity and test offerings as both companies share a dedication to delivering first-class testing experiences to their clients.
"Genophyll enhances our testing services and has a high-quality workforce, who we look forward to welcoming to our company", said Mark Fasciano, CEO of Rover Labs. "We are fully committed to making this transition as seamless as possible for all of our employees and clients alike."
The acquisition of Genophyll fits into Rover Lab's strategy to expand regionally and offer turnkey, cost-effective testing. By purchasing Genophyll, the company has the resources to improve turnaround time, diversify testing options, and expand product and testing services in the tri-state area.
"We currently serve over 200 schools across five counties in NJ. We can now offer our services throughout New Jersey, New York, and Connecticut to any school, business or organization looking to execute large-scale testing effortlessly" said Fasciano.
Genophyll will continue to be a local mainstay providing quick and accurate COVID-19 PCR results within 24 hours. Patients can continue to set appointments Monday through Friday from 9:30am to 7:00pm over the phone (732-945-0190) or through the website (www.genophylllabs.com).
​
About Rover Labs
Rover Labs was established by serial tech entrepreneur Mark Fasciano and Columbia Biomedical Engineering Professor Sam Sia to meet the NY-metro area's need for more efficient and comfortable COVID-19 testing. Rover Labs has a strategic partnership with Rover Diagnostics, a Columbia University spinout that was part of the NIH's Rapid Acceleration of Diagnostics (RADx) program to fast-track COVID testing innovation. For more information about Rover Labs please visit www.rover-labs.com.
Contact Information
Mark Fasciano
CEO, Rover Labs